3 results about "Neuroprotective factors" patented technology

This disclosure provides compositions and methods for detecting, methods for predicting a risk of developing, and methods for treating systemic and brain parenchymal metastases including leptomeningeal disease (LMD). In particular, provided herein are methods for detecting and / or predicting a risk of developing systemic and brain parenchymal metastases including LMD in a subject (e.g., a human subject) through identifying the presence or absence of integrin a6 and / or breast cancer cells (BCCs) expressing integrin a6 in a sample obtained from the subject. In addition, provided herein are methods for treating, ameliorating, or preventing systemic and brain parenchymal metastases including LMD in a subject through inhibiting expression and / or activity of one or more of integrin a6, BCCs expressing integrin a6, neuroprotective factor glial cell line-derived neurotrophic factor (GDNF), and neural cell adhesion molecule (NCAM).

This invention belongs to the field of biomedicine and provides the application of LAPF and its agonists in the preparation of drugs for the treatment or prevention of postherpetic neuralgia. This invention targets spinal microglia by administering LAPF protein, a gene vector encoding LAPF, or an upregulator of their expression / activity, restoring their antiviral immune function, inhibiting neuroinflammation, and promoting the expression of neuroprotective factors. Animal experimental results show that administering LAPF protein, a gene vector encoding LAPF, or an upregulator of their expression / activity can significantly reduce mechanical hyperalgesia, decrease HSV-1 / VZV-related nerve damage, and effectively alleviate symptoms of chronic neuralgia.

The invention provides engineered mesenchymal stromal cells (ePSCs) with a phagocytosis function and an application of the engineered mesenchymal stromal cells (ePSCs) in treatment of Alzheimer's disease (AD). The engineered mesenchymal stromal cells (ePSCs) are obtained by inducing fibroblasts to be reprogrammed by adopting a chemical small molecule combination. The invention discloses a set of genetic modification-free reprogramming scheme based on a chemical small molecule composition, which is used for efficiently converting fibroblasts from somatic cells into ePSCs (enhanced pluripotent stem cells) by sequentially activating an endogenous reprogramming pathway. The obtained ePSCs highly express phagocytic function related proteins (including TMEM119, SCARB1, APOE, CTSD and the like), and the ability of removing beta amyloid protein (A beta) plaques is significantly enhanced. In-vitro and in-vivo AD model verification proves that transplanted ePSCs can be directionally migrated to an intracerebral lesion area, and through a synergistic effect mechanism: (i) directly phagocytizing and degrading A beta aggregates, and (ii) providing neuroprotective factors (such as HTRA1, GLUL, SLIT1, TUBB3 and NPTX2) to inhibit neuroinflammatory response, promote nerve regeneration, effectively improve the neuron survival state and synaptic function integrity, and improve the neurological activity of the brain. And finally, cognitive function recovery is promoted.